Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfizer's sorbinil

Executive Summary

Randomized, placebo-controlled study on long-term efficacy of sorbinil, published in the Sept. 1 New England Journal of Medicine. Study concludes that the aldose reductase inhibitor, "as a metabolic intervention targeted against a specific biochemical consequence of hyperglycemia, can improve the neuropathologic lesions of diabetic neuropathy." The study is part of the Pfizer/National Eye Institute's large, multicenter investigation of sorbinil. It found that the 10 sorbinil-treated patients had a 42% decrease in nerve sorbitol content and a 3.8 fold increase in the percentage of regenerating myelinated nerve fibers after one-year of treatment. Pfizer said it expects analysis of all sorbinal trial data to be completed later this year. The company has begun considering related compounds.

You may also be interested in...

Win For Axonics As England’s NICE Says Rechargeable Neuromodulation Is Cost-Effective

Health technology assessment body NICE is consulting on draft guidance that recommends Axonics' device for overactive bladder.

With BMS Set To Join, What Next For CAR-T Market?

CAR-T therapies are groundbreaking in clinical terms, but have hit barriers in uptake. Can BMS’s challenger go one better than Yescarta and Kymriah?

Biopharma Quarterly Dealmaking Statistics, Q4 2019

Financing for biopharma companies increased by 19% in Q4 to $15.8bn. M&A value quadrupled, compared with Q3, thanks to nine billion-dollar-plus transactions, led by the buy-out of Nestle Skin Health, now Galderma.Among the key alliances of Q4 were recurring themes of gene therapy and oncology, but also big investments in oligonucleotide technologies.



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts